Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS.
Handunnetti SM, et al. Among authors: thompson pa.
Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388. Online ahead of print.
Blood. 2024.
PMID: 38662991
With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) allowed after protocol amendment for patients in MRD-negative CR. ...Newly emergent or increasing cardiovascula …
With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective …